ABL Diagnostics Deepens Laboratory Footprint with Launch of HybridChek for HIV and Tuberculosis Whole Genome Sequencing
By Offering Amplicon and Hybrid Capture on a Single Bioinformatics platform, the Company Expands Capabilities to Cover All Pathogen Sequencing Needs. WOIPPY, FRANCE, June 8, 2026 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), an …